SCHEMBL2476718

SCHEMBL2476718

COCc1nc2c(=O)[nH]c(=O)n(CC(C)C)c2n1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
PDE1A P54750 4/20 0.45
PDE1B Q01064 4/20 0.45
PDE1C Q14123 4/20 0.45
PDE5A O76074 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
BLM P54132 1/20 0.45
PDE2A O00408 2/20 0.42
KDM4E B2RXH2 6/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 5/20 0.39
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937183 0.81 KDM4E (0.43) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL7624092 0.80 KDM4E (0.42) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL1804901 0.77 KDM4E (0.41) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL4377951 0.75 KDM4E (0.52) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL4623478 0.71 KDM4E (0.38) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL5647 0.70 ADORA2A (0.43) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL9765951 0.66 ADORA2A (0.49) MEN1KMT2ATSHRKDM4EALDH1A1
SCHEMBL4796600 0.66 PDE4A (0.47) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL23797830 0.66 HTT (0.42) MEN1KMT2APDE1APDE1BPDE1C
SCHEMBL3524432 0.66 KDM4E (0.35) MEN1KMT2APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638265-A1 REPROGRAMMING FIBROBLASTS TO RETINAL CELLS University of North Texas Health Science Center (US) 2020-04-22 EP disclosed
EP-3525788-A1 TREATMENT OF SYNUCLEINOPATHIES Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) 2019-08-21 EP disclosed
WO-2018232258-A1 REPROGRAMMING FIBROBLASTS TO RETINAL CELLS UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) 2018-12-20 WO disclosed
WO-2018069312-A1 TREATMENT OF SYNUCLEINOPATHIES DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) 2018-04-19 WO disclosed
WO-2011146819-A2 METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES DMD THERAPIES, LLC (US) 2011-11-24 WO disclosed
EP-2370080-A1 PDE1 AS A TARGET THERAPEUTIC IN HEART DISEASE University of Utah Research Foundation (US) 2011-10-05 EP disclosed
WO-2010065617-A1 PDE1 AS A TARGET THERAPEUTIC IN HEART DISEASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2010-06-10 WO disclosed
WO-2010002492-A1 METHODS OF USE OF ADENINE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISORDERS UNIVERSITY OF CHICAGO (US) 2010-01-07 WO disclosed
WO-2009002507-A1 COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS COMBINATORX, INCORPORATED (US) 2008-12-31 WO disclosed
WO-2008157205-A2 METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP DUKE UNIVERSITY (US) 2008-12-24 WO disclosed
WO-2007103373-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2007-09-13 WO disclosed
WO-2007089617-A2 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH COMBINATORX, INCORPORATED (US) 2007-08-09 WO disclosed
WO-2007079293-A2 CANCER STEM CELLS AND USES THEREOF HOSPITAL FOR SICK CHILDREN (CA) 2007-07-12 WO disclosed
WO-2007056457-A2 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS COMBINATORX, INCORPORATED (US) 2007-05-18 WO disclosed
EP-1583541-A2 COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS Neuronova AB (SE) 2005-10-12 EP disclosed
WO-2004045592-A2 COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS NEURONOVA AB (SE) 2004-06-03 WO disclosed
EP-1305328-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES Lyles, Mark B. (US) 2003-05-02 EP disclosed
WO-2002008237-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES LYLES MARK B (US) 2002-01-31 WO disclosed
WO-2001068137-A2 COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION BROWN UNIVERSITY RESEARCH FOUNDATION (US) 2001-09-20 WO disclosed
WO-1995009636-A1 METHOD OF INDUCING VASORELAXATION TO TREAT PULMONARY HYPERTENSION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) 1995-04-13 WO disclosed